Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis

E. Danese; M. Montagnana; J. A. Johnson; A. E. Rettie; C. F. Zambon; S. A. Lubitz; G. Suarez-Kurtz; L. H. Cavallari; L. Zhao; M. Huang; Y. Nakamura; T. Mushiroda; M. K. Kringen; P. Borgiani; C. Ciccacci; N. T. Au; T. Langaee; V. Siguret; M. A. Loriot; H. Sagreiya; R. B. Altman; M. H. A. Shahin; S. A. Scott; S. I. Khalifa; B. Chowbay; I. M. Suriapranata; M. Teichert; B. H. Stricker; M. Taljaard; M. R. Botton; J. E. Zhang; M. Pirmohamed; X. Zhang; J. F. Carlquist; B. D. Horne; M. T. M. Lee; V. Pengo; G. C. Guidi; P. Minuz; Cristiano Fava

doi:10.1038/clpt.2012.184

Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis

E. Danese, M. Montagnana, J. A. Johnson, A. E. Rettie, C. F. Zambon, S. A. Lubitz, G. Suarez-Kurtz, L. H. Cavallari, L. Zhao, M. Huang, Y. Nakamura, T. Mushiroda, M. K. Kringen, P. Borgiani, C. Ciccacci, N. T. Au, T. Langaee, V. Siguret, M. A. Loriot, H. SagreiyaR. B. Altman, M. H. A. Shahin, S. A. Scott, S. I. Khalifa, B. Chowbay, I. M. Suriapranata, M. Teichert, B. H. Stricker, M. Taljaard, M. R. Botton, J. E. Zhang, M. Pirmohamed, X. Zhang, J. F. Carlquist, B. D. Horne, M. T. M. Lee, V. Pengo, G. C. Guidi, P. Minuz, Cristiano Fava

Cardiovascular Research - Hypertension

Research output: Contribution to journal › Review article › peer-review

Abstract

A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I-2 = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.

Original language	English
Pages (from-to)	746-756
Journal	Clinical Pharmacology and Therapeutics
Volume	92
Issue number	6
DOIs	https://doi.org/10.1038/clpt.2012.184
Publication status	Published - 2012

Subject classification (UKÄ)

Pharmacology and Toxicology

Access to Document

10.1038/clpt.2012.184

Cite this

Danese, E., Montagnana, M., Johnson, J. A., Rettie, A. E., Zambon, C. F., Lubitz, S. A., Suarez-Kurtz, G., Cavallari, L. H., Zhao, L., Huang, M., Nakamura, Y., Mushiroda, T., Kringen, M. K., Borgiani, P., Ciccacci, C., Au, N. T., Langaee, T., Siguret, V., Loriot, M. A., ... Fava, C. (2012). Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis. Clinical Pharmacology and Therapeutics, 92(6), 746-756. https://doi.org/10.1038/clpt.2012.184

@article{d5cffcd1cdda469abf65c5342ab69a61,

title = "Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis",

abstract = "A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I-2 = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.",

author = "E. Danese and M. Montagnana and Johnson, {J. A.} and Rettie, {A. E.} and Zambon, {C. F.} and Lubitz, {S. A.} and G. Suarez-Kurtz and Cavallari, {L. H.} and L. Zhao and M. Huang and Y. Nakamura and T. Mushiroda and Kringen, {M. K.} and P. Borgiani and C. Ciccacci and Au, {N. T.} and T. Langaee and V. Siguret and Loriot, {M. A.} and H. Sagreiya and Altman, {R. B.} and Shahin, {M. H. A.} and Scott, {S. A.} and Khalifa, {S. I.} and B. Chowbay and Suriapranata, {I. M.} and M. Teichert and Stricker, {B. H.} and M. Taljaard and Botton, {M. R.} and Zhang, {J. E.} and M. Pirmohamed and X. Zhang and Carlquist, {J. F.} and Horne, {B. D.} and Lee, {M. T. M.} and V. Pengo and Guidi, {G. C.} and P. Minuz and Cristiano Fava",

year = "2012",

doi = "10.1038/clpt.2012.184",

language = "English",

volume = "92",

pages = "746--756",

journal = "Clinical Pharmacology and Therapeutics",

issn = "1532-6535",

publisher = "Nature Publishing Group",

number = "6",

}

Danese, E, Montagnana, M, Johnson, JA, Rettie, AE, Zambon, CF, Lubitz, SA, Suarez-Kurtz, G, Cavallari, LH, Zhao, L, Huang, M, Nakamura, Y, Mushiroda, T, Kringen, MK, Borgiani, P, Ciccacci, C, Au, NT, Langaee, T, Siguret, V, Loriot, MA, Sagreiya, H, Altman, RB, Shahin, MHA, Scott, SA, Khalifa, SI, Chowbay, B, Suriapranata, IM, Teichert, M, Stricker, BH, Taljaard, M, Botton, MR, Zhang, JE, Pirmohamed, M, Zhang, X, Carlquist, JF, Horne, BD, Lee, MTM, Pengo, V, Guidi, GC, Minuz, P & Fava, C 2012, 'Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis', Clinical Pharmacology and Therapeutics, vol. 92, no. 6, pp. 746-756. https://doi.org/10.1038/clpt.2012.184

TY - JOUR

T1 - Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis

AU - Danese, E.

AU - Montagnana, M.

AU - Johnson, J. A.

AU - Rettie, A. E.

AU - Zambon, C. F.

AU - Lubitz, S. A.

AU - Suarez-Kurtz, G.

AU - Cavallari, L. H.

AU - Zhao, L.

AU - Huang, M.

AU - Nakamura, Y.

AU - Mushiroda, T.

AU - Kringen, M. K.

AU - Borgiani, P.

AU - Ciccacci, C.

AU - Au, N. T.

AU - Langaee, T.

AU - Siguret, V.

AU - Loriot, M. A.

AU - Sagreiya, H.

AU - Altman, R. B.

AU - Shahin, M. H. A.

AU - Scott, S. A.

AU - Khalifa, S. I.

AU - Chowbay, B.

AU - Suriapranata, I. M.

AU - Teichert, M.

AU - Stricker, B. H.

AU - Taljaard, M.

AU - Botton, M. R.

AU - Zhang, J. E.

AU - Pirmohamed, M.

AU - Zhang, X.

AU - Carlquist, J. F.

AU - Horne, B. D.

AU - Lee, M. T. M.

AU - Pengo, V.

AU - Guidi, G. C.

AU - Minuz, P.

AU - Fava, Cristiano

PY - 2012

Y1 - 2012

N2 - A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I-2 = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.

AB - A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I-2 = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.

U2 - 10.1038/clpt.2012.184

DO - 10.1038/clpt.2012.184

M3 - Review article

C2 - 23132553

SN - 1532-6535

VL - 92

SP - 746

EP - 756

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 6

ER -

Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this